chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It started as a pain/pressure in my chest that was initially annoying but progressively got worse. I woke up in the middle of the night and the pain had worsened so I went to the emergency room but the pain subsided about an hour and a half in the ER however that is when it was discovered that I had Myocarditis. I was admitted into the hospital for 2 days with a series of test like EKG, stress tests, attempted MRI and several others. Once they had established to a reasonable degree that there was no damage to my heart, I was released late that evening and place on Metoprolol for 3 months. I have since had a series of follow up visits to cardiologist. Most recently 1 month ago 12-12-2021. I was taken off the medication but was asked to continue having my heart monitored.
Fever and chills started on 4/14/21. Approximately 36 hours later she noticed a small rash appearing on her left upper arm. Around  48 hours the rash was about 5x3 inches wide and splotchy. No current treatment.
Dizziness: persistent feeling of dizziness that will not go away since March 29, 2021, 1 day following vaccine Pfeizer dose 1.
Thursday afternoon started to feel a little off and through the evening. Friday 31MAR2023  when  woke I felt ill and every joint hurt aches and and pains I never had a fever this prompted me to do a COVID-19 Test-Positive and it continued throughout the day. I called my Doctor and the nurse called me back .It was recommended to take Advil and Tylenol. I started to develop sinus and chest congestion. I took  cough medicine Delsym  32MAR2023 Saturday I continued the regiment every twelve hours on Saturday I just felt horrible no fever but literally did nothing on Sunday started to fell a little better and never developed heavy chest congestion a lessening of the symptom but lost taste and smell and this now has continue to improve as of Tuesday the lasting symptoms are nasal congestion and aching in my hip joints but Advil takes care of that and today I feel pretty damn good. I felt well enough yesterday and today but still lack of smell and taste but was able to cut the lawn.
Doses administered past the published expiry; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry) in a 69-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Sep-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 16-Sep-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Doses administered past the published expiry) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications reported. No treatment reported.
swelling and redness at the injection site arm pain at the injection  site itching at the injection site fatigue/tiredness sweeting Everything started within the first hour of injection and continued for 3 days; today is day 4 and i'm starting to experience some relief, although the injection site still itches
sinus h/a, sore throat, ache in joints; no fever; 8PM c/o CP radiating to lt arm & jaw; MI r/o'd; etiology unk; enzymes neg;
Pain and heat at the injection site; Pain and heat at the injection site; Mild muscle / joint pain; Mild muscle / joint pain; A spontaneous report was received from a consumer concerning a female patient who received Moderna's COVID-19 vaccine (mRNA-1273) experienced pain and heat at the injection site and mild muscle / joint pain.    The patient's medical history was not provided. Concomitant product use was not provided by the reporter.   On 23 Dec 2020, prior to the onset of the symptoms, the patient received their planned dose of mRNA-1273 (Batch number not provided) intramuscularly for prophylaxis of COVID-19 infection.   On unknown date, the patient experienced pain and heat the injection site. She also experienced mild muscle and joint pain.  Treatment information was not provided.    Action taken with mRNA-1273 in response to the events was not provided.  The outcome of the events pain and heat at the injection site and mild muscle / joint pain were unknown.; Reporter's Comments: This case concerns a female of unknown age who experienced a NS unexpected events of injection site warmth and NS expected events of injection site pain, myalgia, arthralgia.  The events occurred with unknown latency after the first dose of mRNA-1273. Treatment not reported. Event outcomes unknown. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
MORNING FOLLOWING EVENING VACCINATION PATIENT NOTICED SMALL AMOUNT OF REDNESS DIRECTLY AROUND THE INJECTION SITE, REDNESS PROGRESSIVLY GOT WORSE THROUGHOUT TUESDAY. PATIENT CONTACTED THE PHARMACY WEDNESDAY AFTERNOON TO INFORM OF THE REACTION. PATIENT ALSO NOTED LOW GRADE FEVER TUESDAY (99.7) WHICH HAD RESOLVED BY WEDNESDAY MORNING. PATIENT WAS COUNSELLED ON POSSIBLE REACTIONS TO VACCINATION AND WAS TOLD TO DRAW A LINE OF DEMARKATION AROUND THE REDNESS. WEDNESDAY EVENING PATIENT PRESENTED AT PHARMACY WITH REDNESS SPANNING JUST OVER 3 INCHES IN DIAMETER, WITH REDNESS MOVING OUTSIDE OF THE LINE MARKED EARLIER. PATIENT WAS COUNSELLED TO TAKE BENADRYL, ICE THE AREA, AND USE TOPICAL HYDROCORTISONE WITH ALOE. PATIENT WAS ALSO INSTRUCTED TO CONTACT PCP TO INFORM THEM OF REACTION. PATIENT WAS CONTACTED THURSDAY MORNING AND REPORTED NO ADDITIONAL FEVER, REDNESS MOVING MORE DOWN THE LEFT ARM SURPASSING THE LINE DRAWN BY ABOUT AN INCH. PATIENT WAS AGAIN INSTRUCTED TO CONTACT PCP.
itchiness at shoulder to elbow, rashes; itchiness at shoulder to elbow, rashes; This spontaneous case was reported by a consumer and describes the occurrence of RASH (itchiness at shoulder to elbow, rashes) and PRURITUS (itchiness at shoulder to elbow, rashes) in a 94-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 337K20A) for COVID-19 vaccination.     The patient's past medical history included Panic attack and Sneezing. Concomitant products included LORAZEPAM for Panic attack, DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Sneezing.    On 18-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-Jan-2021, the patient experienced RASH (itchiness at shoulder to elbow, rashes) and PRURITUS (itchiness at shoulder to elbow, rashes). At the time of the report, RASH (itchiness at shoulder to elbow, rashes) and PRURITUS (itchiness at shoulder to elbow, rashes) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no treatment information provided
I had high blood pressure and was prescribed high blood pressure medication. I also experienced headaches and symptoms associated with high blood.
Dizziness and nausea 4 hours. To ER; given Benadryl and chest pain 6 hours. Nitro patch; EKG and blood work negative for MI. Medical records state vertigo, vestibular disorder. msv
This case was reported by a healthcare professional and described the occurrence of lump at the injection site in a 39-year-old female subject who was vaccinated with FLULAVAL (GlaxoSmithKline). There were no concurrent medications. On 2 September 2008 at 10:00 the subject received unspecified dose of FLULAVAL at 0.5 ml, subcutaneously, in the left arm. On 3 September 2008, 24 hours after vaccination with FLULAVAL, the subject experienced lump at the injection site, injection site warmth and injection site redness. The drug was also
Sweating more; Odor on my skin; dont have sensitive teeth and I am not getting those headaches anymore; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (Sweating more), SKIN ODOUR ABNORMAL (Odor on my skin) and THERAPEUTIC RESPONSE UNEXPECTED (dont have sensitive teeth and I am not getting those headaches anymore) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPERHIDROSIS (Sweating more), SKIN ODOUR ABNORMAL (Odor on my skin) and THERAPEUTIC RESPONSE UNEXPECTED (dont have sensitive teeth and I am not getting those headaches anymore). At the time of the report, HYPERHIDROSIS (Sweating more), SKIN ODOUR ABNORMAL (Odor on my skin) and THERAPEUTIC RESPONSE UNEXPECTED (dont have sensitive teeth and I am not getting those headaches anymore) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Concomitant medications were reported No treatment medications were reported
APHASIA; LYMPHOEDEMA; DIPLOPIA; DYSGEUSIA; BURNING SENSATION; DIARRHOEA; Pain in extremity; RASH; HEADACHE; FATIGUE; This spontaneous case was reported by a consumer and describes the occurrence of APHASIA (APHASIA), LYMPHOEDEMA (LYMPHOEDEMA), DIPLOPIA (DIPLOPIA), DYSGEUSIA (DYSGEUSIA) and BURNING SENSATION (BURNING SENSATION) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 01-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced APHASIA (APHASIA), LYMPHOEDEMA (LYMPHOEDEMA), DIPLOPIA (DIPLOPIA), DYSGEUSIA (DYSGEUSIA), BURNING SENSATION (BURNING SENSATION), DIARRHOEA (DIARRHOEA), PAIN IN EXTREMITY (Pain in extremity), RASH (RASH), HEADACHE (HEADACHE) and FATIGUE (FATIGUE). At the time of the report, APHASIA (APHASIA), LYMPHOEDEMA (LYMPHOEDEMA), DIPLOPIA (DIPLOPIA), DYSGEUSIA (DYSGEUSIA), BURNING SENSATION (BURNING SENSATION), DIARRHOEA (DIARRHOEA), PAIN IN EXTREMITY (Pain in extremity), RASH (RASH), HEADACHE (HEADACHE) and FATIGUE (FATIGUE) outcome was unknown.            Concomitant medication was not reported.  No treatment medication was reported.
pt recvd vax & 10 mins p/vax exp burning, stinging, SOB, tight chest; dx w/panic attack;
UTI; Frequent urination; amber to brown urine; tasted bitter; This is a spontaneous report from a non contactable consumer reported similar events for herself, her husband and 2 other people. This report is for reporter self. A 66-Year-old non-pregnant female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration into the left arm on 16Feb2021 12:15 PM (at the age of 66-years-old) as dose 2, single for covid-19 immunization. No medical history and concomitant medications were not reported. It was reported that the patient had no allergies and other medical history. The patient previously took historical vaccine dose 1 on an unspecified date for covid-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not diagnosed with COVID-19 prior to vaccination. On an unspecified date patient experienced feeling like she had UTI(urinary tract infection), frequent urination, amber to brown urine. Everything she put into her mouth tasted bitter for a day. Had shot Sunday and everything still tastes bitter. It's Tuesday. The patient did not received any treatment for adverse events. The clinical outcome of the events were not recovered.  No follow-up attempts are Possible. Information on lot/batch cannot be obtained.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021225203 same reporter/drug with different patient, similar AE;US-PFIZER INC-2021225201 same reporter/drug with different patient, similar AE;US-PFIZER INC-2021225202 same reporter/drug with different patient, similar AE
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown demographics. On an unknown date on unspecified number of patients were vaccinated with RECOMBIVAX HB (dose, lot and expiry date was unknown). The vaccine was exposed to 28 Fahrenheit for 15 days, an excursion that was found to be unsupported by in-house stability data. No adverse symptoms were reported. The nurse was unable to provide administration dates and well as lot and expiration dates for the vaccine involved. This is 1 of 3 reports by the same reporter. Additional information has been requested.
Started with pain in neck that spread up to head, achy, fever and rash on arm.
Patient reports that approximately 2.5 weeks after getting first dose of vaccine, he noticed swelling in his left hand and wrist and had had pain going up his left arm.  He described it as a "nagging, aching sensation".  He reports that after receiving the vaccine, no bandaid was placed over the injection site.
Patient reported to Pharmacy injection site rash, with tenderness on 9/08/2021.      Rash around injection site was about 6 inches in diameter and warm to the touch at the time patient presented to pharmacy.   The right arm lymph nodes were enlarged.
Onset of tinnitus in right ear.  Significant ringing, hissing and diminished/muted hearing along with mild pain and sensitivity to sound.  Debilitating condition causing distress and difficulty concentrating.
dry cough; injection site was itchy; Fatigue; sleepy; injection site was swollen and sore; injection site was swollen and sore; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 28 year-old female patient (unknown if pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 23Aug2021 18:00 (Lot number: FC3181) at the age of 28 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Glucose-6-phosphate dehydrogenase deficiency" (unspecified if ongoing), notes: Other medical history: G6PD Deficiency; "sulfa based madicine" (unspecified if ongoing), notes: Known allergies: sulfa based medicine; "Yes - favs beans" (unspecified if ongoing), notes: Known allergies: Yes - favs beans. There were no concomitant medications. Vaccination history included: Bnt162b2 (Product: COVID 19, Brand: Pfizer, Lot number: EW0181, Lot unknown: False, Administration date: 02Aug2021, Administration time: 02:00 PM, Dose number: 1, Vaccine location: Right arm), administration date: 02Aug2021, when the patient was 28 years old, for COVID-19 immunisation. The following information was reported: COUGH (non-serious) with onset 28Aug2021, outcome "recovering", described as "dry cough"; FATIGUE (non-serious) with onset 24Aug2021, outcome "recovering", described as "Fatigue"; SOMNOLENCE (non-serious) with onset 24Aug2021, outcome "recovering", described as "sleepy"; VACCINATION SITE SWELLING (non-serious), VACCINATION SITE PAIN (non-serious) all with onset 24Aug2021, outcome "recovering" and all described as "injection site was swollen and sore"; VACCINATION SITE PRURITUS (non-serious) with onset 28Aug2021, outcome "recovering", described as "injection site was itchy". Therapeutic measures were not taken as a result of cough, fatigue, somnolence, vaccination site swelling, vaccination site pain, vaccination site pruritus. No follow-up attempts are possible. No further information is expected. Follow-up attempts are completed. No further information is expected.
may be shingles; patient developed rashes on the right shoulder/at the beginning size of rash looked like index finger but now look like 3 fingers/ Some rashes are red with head and other are white clear; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (may be shingles) and RASH (patient developed rashes on the right shoulder/at the beginning size of rash looked like index finger but now look like 3 fingers/ Some rashes are red with head and other are white clear) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 06-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Jun-2021, the patient experienced RASH (patient developed rashes on the right shoulder/at the beginning size of rash looked like index finger but now look like 3 fingers/ Some rashes are red with head and other are white clear). On an unknown date, the patient experienced HERPES ZOSTER (may be shingles). At the time of the report, HERPES ZOSTER (may be shingles) and RASH (patient developed rashes on the right shoulder/at the beginning size of rash looked like index finger but now look like 3 fingers/ Some rashes are red with head and other are white clear) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medication was provided.  Patient developed rashes on the right shoulder and at the beginning the size rash looked like index finger but now look like 3 fingers. Some rashes are red with head and other are white clear. The caller mentioned that may be shingles. She wanted to know what to do and asked medication to use.
This spontaneous report was received from a physician via a company representative concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions, drug reactions/allergies and concomitant medications were unknown by the reporter. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX 19400 plaque forming units (PFU), as prophylaxis (Dose, route, lot # and expiration date were not reported). On an unknown date, the patient experienced anaphylactic shock after receiving ZOSTAVAX. It was unknown if treatment was given for the event or if lab diagnostics studies were performed to the patient. The outcome of anaphylactic shock was unknown. The reporter did not provide the causality between the events and ZOSTAVAX. Upon internal review, anaphylactic shock was determined to be medically significant. Additional information has been requested.
When I first got the vaccine 24 hours later I just and a sore arm and then about a month after. I woke up did a breathing treatment and that did not do anything, and I did a second breathing treatment and that did not work so I went to ER and they put me on Prednisone for 7 days and gave me Augmentin for 10 days and I also received 2 breathing treatments in the ER. It seemed to improve after the steroid therapy. My breathing has gotten worse my PFT was 85% now I'm at 67-75%. I'm on the frontlines since day one.
Developed progressive generalized severe muscular aching throughout body. Onset 2 hrs, duration 3-4 weeks. Required MD visit, Vioxx and Vicodin to cope with pain. Medications alleviated generalized pain but arm remained sore to the point of difficulty in use, for another week.
Patient and parents described urticarial wheals to her torso and arms, relieved after several doses of diphenhydramine elixir 12.5 mg/5 mL strength. She had itching to said areas and a headache, with some nausea, but no active vomiting. She felt also unwell after the 1st dose of the same vaccine, given on 14 JULY 2021.
Arm that received vaccine was more sore the second time than the first. Vaccine was given at 8:45 am and felt very tired about 5:00pm. Only slight aches in upper body at night. Next day, no symptoms other than minimal arm pain at injection site.
Patient received vaccine, 5 minutes into the 15 minute observation waiting period patient's husband, who also received a vaccine, was in a panic-like state and reported he was not feeling well, pharmacist on duty asked if she needs to call 911, which he responded yes. While on the phone, patient's husband reported that she lost consciousness. EMS came to the scene and took over, patient and husband left with EMS 10 to 15 minutes later.
This spontaneous report as received from a other health professional refers to a unspecified patient of unknown age and gender. On an unknown date the patient was vaccinated with ROTATEQ (lot numbers M038728 and M041184) oral for prophylaxis. On an unknown date, the vaccine was incorrectly storage. Sender's Comments: US-009507513-1708USA012512: US-009507513-1708USA012513.
Reported Symptoms: 10010300:CONFUSION;  10014625:ENCEPHALOPATHY;  10043071:TACHYCARDIA; 10084268:COVID-19;    Narrative: Patient received three doses of Pfizer and one dose of Moderna COVID 19 vaccine.  The  patient presented to the ED on 6 November 2022 with confusion and  tachycardia.  The patient was admitted with COVID 19.   The patient was  treated with diltiazem.  The patient was discharged on 16 November 2022 in  stable condition.  Reported per EUA.  Other Relevant HX:  Other: covid encephalopathy
This is a spontaneous report from a contactable consumer. A 66-year-old male patient received second dose of bnt162b2 (BNT162B2), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) (vaccinated at 66-year-old) as DOSE 2, SINGLE for covid-19 immunisation. Medical history included cataracts. Patient received first dose on an unspecified date. The patient's concomitant medications were not reported. The patient experienced cataracts got worse after second dose. Unknown if treatment received. The outcome of event was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Moderate swelling to left upper arm increased pain, states 10/10 pain. Increased warmth to area.
Patient experienced a black and blue bruise on his upper left arm a few days after the shot he was instructed by doctor to place on ice pack on his reaction and take TYLENOL.
A 12+ of the Pfizer COVID-19 vaccine was administered to a patient that was under 12 years old. There are no known effects at this time.
no adverse effects; improperly stored VARIVAX; Information has been received from a medical assistant, concerning a patient of unknown age and gender. The patient's pertinent medical history, previously drug reactions, allergies, concurrent conditions and concomitant medication were not reported.      On 14-JUN-2019, the patient was vaccinated with improperly stored varicella virus vaccine live (oka/merck) (VARIVAX) lot number R035226 with expiration date in 04-DEC-2020 (strength, anatomical location, dose and route of administration were not provided) for prophylaxis, that was reconstituted with sterile diluent (DILUENT MRK) (strength, dose, lot number, expiration date and route of administration were not provided) (it was not reported if the sterile diluent (DILUENT MRK) used had an excursion).   The varicella virus vaccine live (oka/merck) (VARIVAX) was stored at a temperature range of -9 degrees Celsius (°C) to 8°C (-3°C), for the time frame of 3 hours and 39 minutes. There was no previous temperature excursion and the call was because of a data logger.   No adverse effects were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-1906USA008662: